R21-Matrix/M Vaccine (malaria vaccine)
PreclinicalVaccine
R21-Matrix/M Vaccine (malaria vaccine) is one of 21 biologic programs targeting Malaria. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
479 competitors in Malaria
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Stelara
Johnson & JohnsonPreclinical
Hydroxychloroquine Sulfate
NovartisPreclinical
Iron
WWatson Pharmaceuticals
Preclinical
IV LBH589
NovartisPreclinical
Mefloquine Plus Artesunate
Medicines for Malaria VenturePreclinical
IV Ceftriaxone
RRESnTEC, Institute of Research
Preclinical
RTS,S/AS01E
GSKPreclinical
Malarone
Medicines for Malaria VenturePreclinical
Piperaquine
UUniversity of Oxford
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Preclinical[1]
- Company
- NNicole Stoffel